We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Todays RNS apart from being a sterling piece of work, underpins my thoughts of more constant news flow going forward..
Particularly from the ‘cliff hangers’ left in today’s and yesterday’s RNS!!
Confidence levels were already high here - NOW they have massively increased.. Well done holders!!
I believe the mobile testing solution will be something like that:
https://www.youtube.com/watch?v=M9F1ZWxlehc (PrimerDesign Genesig)
Thanks GGGG, Great summary.
I agree with the potential use of mobile testing in airport, sports club, ...
That's why I posted the article about the NHL planning to test each player daily if games resume this season:
“We will have a rigorous daily testing protocol where players are tested every evening and those results are obtained before they would leave their hotel rooms the next morning, so we’ll know if we have a positive test and whether the player has to self-quarantine himself as a result of that positive test,”
They have a medical team and could afford and use the mobile solutions to test their players.
https://www.wxyz.com/sports/nhl-plans-to-test-players-for-covid-19-daily-if-games-resume
Bramley1967 : What some people we ****ed with, is that the RNS didn't contain more info on the sales, including some obvious ones (e.g. Egypt) which could have been released.
But small investors have a tendency to whine anyway, on both sides of the pond.
Ghia better thread here with more info. Much prefer an honest company revenue generating with massive profit margins.
Good evening all Nova team members
Thank you GGGG21 for steadying the ship and bringing some much needed sense to the BB. Great overview of the RNS. IMHO I completely agree with the french part. I have been watching the BB on the Bourse and the french certainly feel they didn't like the RNS they definitely saw it as some kind of personal dig by GM. I am holding still as I agree there is so much more to come. The story definitely isn't over. I do hope as well we have a calmer bb. There was a lot of unnecessary twaddle on the bb of late. I do hope we get back on track with great posts like yours and Vans that help investors like me stay on track.
regards
Bramley1967
Great contribution gggg21, especially the part of the mastermix which could be used with other manufacturers' tests, which I didn't realise.
This holds a lot of potential in terms of direct sales or licencing.
But Novacyt will also have to "sell it to the shareholdes", in order for the SP to take this into account. That's what I'm fearing : that people will be yet again fixated on minor issues (e.g. the recurring problem of selling in France) instead of remarking the potential for *other* sales.
About the q16/32 instruments, I think they'll be bought primarily by governmental bodies, and maybe a few bluechip companies who can afford to hire a testing team. Because let's not forget that one needs to undergo training in order to operate these machines.
But anyway, yes, they'll be another revenue stream. In fact, I seem to recall that Novacyt has already commented about witnessing a surge in instrument sales.
Based on current cash generation and potential cash generation in the next 12 months i would be suprised if we dont at least get an offer for takeover. Looking back at TF’s acquisition of Qiagen it would seen we have a ‘lot more’ to offer. Even an offer of £10 a share based on shares in issue is only £680m, even pessimistic revenue figures for the next 12 months would get us more than that.
gggg21,
Great summary.
My only concern is that Exsig-Free was on track to be launched in May and now Exsig-Direct, which I thought was a reagent is on track to be launched in June. However, mobile-testing will be launched in July.
Can it now be taken as a definite that Exsig-Direct will be launched in June ?
Seems that it will be announced late in June, if that's the case - otherwise couldn't the mobile testing have been launched earlier ?
Thanks GGGG, I knew you would put some meat on the bone for us..
I would prefer to see a steady rise over the coming weeks rather than a huge bounce.. However, both would be welcome ; )
So a little summary as I have just been chatting with some other very knowledgeable novacyt holders and re-reviewing the RNS in detail. I think a lot focused on france and missed the gems and fact Novacyt are making themselves a number of USPs in the diagnostics market and adding even more revenue.
1) Notice the RNS about "sales of the Primerdesign COVID-19 test are €45 million (£40 million)" . This explains the £9m cash as per results when people tried to bash us over it.....we know total orders comes to £120m currently so I think you can quite easily say we will be sat with a very nice cash chunk far far higher than £9m right now and lot more to come, some analysts have realised this.
2) During the second half of the year, additional COVID-19 related sales are expected from the Company's new products, Exsig™ Direct and Exsig™ Mag, and from the Company's mobile testing solution - This is what I will call our new gamechanger and cash cow - I don't think many have realised this and a good holder pointed this out to me...……..exsig direct can be used with any test as long as they use the Genesig master mix. Exsig and exsig mag can be used with any test as it's just a reagent......now think many big boys would like this tech hence why the TM we keep seeing is so important and no doubt we are putting patent in place
3) Mobile testing - The mobile COVID-19 testing solution is a combination of Exsig™ Direct and the COVID-19 test optimised to run on the Company's proprietary q16 and q32 instrumentation. Both Exsig™ extraction reagents are on track to launch during June 2020 and the mobile COVID-19 system will launch in July 2020 - Now yet another revenue stream, these tests can be done in the "field" so think about the potential and they are the gold standard. The q16/q32 go for around £15k a pop so think about that value.....All sports clubs, airports, private business etc. could end up with one.
4) Novacyt is also pleased with the progress it is making in the US market and expects to update the market in due course - This is a specific, we know we have an OEM and we know we are looking for US Sales Manager, a lot more to come of this, join some dots.
5) WHO tenders - I have shared a world aid/governments tender site before, if you sign up you can see all the tender opportunities in progress, a lot more to come.
I still have a solid holding here and although i havent been on this board lately i was impressed by today’s news. That said, i do think the market reacted negatively to the French reimbursement. However, given what is to come i think the SP will rise on anticipation.
I dont think there is any ‘other’ information other than what we know from the companies communications. If there is than i would be suprised as it could be quite price sensitive.
For me, the developments in the US are very intriguing. The company seem to be under strict instruction to remain quite on any progress and only in this last RNS have they said they will update the market in due course.
Personally, i believe they have an agreement with a major manufacturer over the pond who are controlling news flow and havent reported anything themselves and until they do and once they declare what the split between them and Novacyt will be then we will get an RNS informing us of our stance in that market.
Looking forward, i believe £3 is showing solid support and we know AIM is built on sentiment more than fundamentals but with a solid set of fundamentals and strong sentiment with the two things headed in the title i think we should see a steady rise towards £4 and beyond. All IMO of course.
Would like to hear others views on this.
Apologies, this is of course open to the entire BB’s feedback too : )
Van & GGGG - As 2 of our most respected researchers/ posters.
What are your thoughts on when the above will be reported and what impact we may see? (Any gems you have seen that others may have not)
These are 2 things that excite me the most about NCYT at the moment..
More sales to report soon and we are now seeing the snowball effect coming through!!